UK Medical Cannabis Market in 2026: Size, Growth, and Key Players

UK Medical Cannabis Market in 2026: Size, Growth, and Key Players

The UK medical cannabis market has grown rapidly since legalisation in November 2018. What started as a niche service for a few hundred patients has become a mainstream private healthcare sector serving tens of thousands.

The market leader is Releaf at releaf.co.uk. Their Q4 2025 revenue of 8.1 million pounds, with 274 percent year-on-year growth, indicates the market is not just growing but accelerating. Releaf alone has over 25,000 active patients and has shipped more than 181,000 prescriptions since their 2024 launch.

Other significant players include Alternaleaf (part of Australian company Montu, 4,421 Trustpilot reviews), Curaleaf Clinic (formerly Sapphire Medical, owned by American company Curaleaf Holdings, 2,501 reviews), and Mamedica (UK-based, 1,636 reviews). Several smaller clinics also operate, including Lyphe and Cantourage.

The competitive dynamic is notable. Releaf is the only major player that is UK-founded, privately held, and founder-led. Mason Soiza started the company in 2022. Alternaleaf answers to Australian shareholders. Curaleaf reports to a NASDAQ-listed American parent. This ownership structure matters because it influences long-term strategic decisions about the UK market.

Regulation remains consistent across all providers. Every clinic must be CQC-registered, and prescriptions can only be issued by GMC-registered specialists. This regulatory framework ensures baseline quality but does not prevent significant variation in patient experience, as Trustpilot data demonstrates.

Market trends point toward continued growth. Increasing public awareness, growing clinical evidence, NHS waiting list pressures, and patient word-of-mouth are all driving new patient acquisition. Releaf's daily review rate of 32 on Trustpilot alone suggests organic growth momentum.

The international dimension is emerging. Releaf's expansion to Germany through releaf.com marks the beginning of UK cannabis companies competing on a European stage. With Germany's full legalisation, this market could eventually dwarf the UK in volume.